Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
Invirase
National Institutes of Health
Create Alert
Related topics
Related topics
7 relations
Broader (4)
Isoquinolines
Quinolines
Saquinavir
saquinavir mesylate
Saquinavir 200 MG Oral Capsule [Invirase]
Saquinavir Oral Capsule [Invirase]
saquinavir mesylate 500 MG Oral Tablet [Invirase]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
The future of medicinal chemistry.
Torsten M Hoffmann
,
R. Metternich
Angewandte Chemie
2012
Corpus ID: 39900988
Medicinal Chemistry is often referred to as a mature science. We believe that this is a misperception. What is probably more…
Expand
Highly Cited
2004
Highly Cited
2004
Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics.
M. Fröhlich
,
M. Hoffmann
,
J. Burhenne
,
G. Mikus
,
J. Weiss
,
W. Haefeli
British journal of clinical pharmacology
2004
Corpus ID: 26498507
Saquinavir is a selective HIV protease inhibitor with limited systemic bioavailability (4% for the hard gelatin capsule (Invirase…
Expand
Highly Cited
2002
Highly Cited
2002
Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.
M. Martin-Facklam
,
J. Burhenne
,
+4 authors
W. Haefeli
British journal of clinical pharmacology
2002
Corpus ID: 24069157
AIMS Bioavailability of orally administered drugs depends on several factors including active excretion, e.g. by P-glycoprotein…
Expand
2001
2001
Synthesis of nucleoside analogs and new Tat protein inhibitors
A. Ane
,
G. Prestat
,
+6 authors
D. Dubreuil
2001
Corpus ID: 8109943
Two studies, concerning the synthesis of original nucleoside analogs regarded as an application of heterochemistry on…
Expand
Review
1998
Review
1998
Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.
V. Wacher
,
J. A. Silverman
,
Y Zhang
,
L. Benet
Journal of pharmaceutical sciences
1998
Corpus ID: 20314902
Cytochrome P450 3A4 (CYP3A4), the major phase I drug metabolizing enzyme in humans, and the MDR1 gene product P-glycoprotein (P…
Expand
1997
1997
Increase in neutralizing antibody titer against sequential autologous HIV‐1 isolates after 16 weeks saquinavir (invirase) treatment
L. Sarmati
,
E. Nicastri
,
+5 authors
M. Andreoni
Journal of medical virology
1997
Corpus ID: 28608710
The humoral immune response to HIV infection plays an important role in determining disease progression. Few and discordant…
Expand
1996
1996
Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.
MMWR. Morbidity and mortality weekly report
1996
Corpus ID: 25134566
In 1995 and 1996, the Food and Drug Administration (FDA) approved three products in the new protease inhibitor class of drugs…
Expand
1996
1996
Two new protease inhibitors approved by FDA. Food and Drug Administration.
G. Folkers
NIAID AIDS agenda
1996
Corpus ID: 28251693
The Food and Drug Administration (FDA) approved two new protease inhibitors--ritonavir and indinavir--for the treatment of HIV…
Expand
1995
1995
Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers.
J. James
AIDS treatment news
1995
Corpus ID: 42637469
Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the…
Expand
1995
1995
Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers.
James Js
1995
Corpus ID: 74769421
: Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE